Document is current
Any future updates will be listed below
-
Authors
Aucouturier, Camille
Soirat, Nicolas
Castéra, Laurent
Bertrand, Denis
Atkinson, Alexandre
Lavolé, Thibaut
Goardon, Nicolas
Quesnelle, Céline
Levilly, Julien
Barbachou, Sosthène
Legros, Angelina
Caron, Olivier
Crivelli, Louise
Denizeau, Philippe
Berthet, Pascaline
Ricou, Agathe
Boulouard, Flavie
Vaur, Dominique
Krieger, Sophie
Leman, Raphael
-
Funding
Funding for this research was provided by:
French Cancéropôle Nord-Ouest (2018/06)
- License Information
-
More Information
Article History
Received: 30 April 2024
Accepted: 28 August 2024
First Online: 30 September 2024
Declarations
:
: All negative controls were from a CASOHAR (CAncer du Sein et/ou de l’Ovaire Héréditaire – ARN, N°ID-RCB 2015-A00598-41) clinical trial and were submitted to and approved by the ethics committee (NTC02560818), <i>Comité de Protection des Personnes CPP Nord Ouest III</i>. All participants gave informed consent for genetic analysis and were approved by the French Biomedicine Agency.
: Not applicable.
: All authors except N.S. and D.B. declare that they have no competing interests. N.S. is employed by SeqOne Genomics for the time period October 2020 to present in the context of a public-private PhD project (CIFRE fellowship #2020/0103) partnership between INSERM and SeqOne Genomics. D.B. is employed by SeqOne Genomics as Head Bioinformatics.
